Design Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Design Therapeutics's estimated annual revenue is currently $8.4M per year.
- Design Therapeutics's estimated revenue per employee is $114,081
- Design Therapeutics's total funding is $170.7M.
- Design Therapeutics's current valuation is $882.3M. (January 2022)
Employee Data
- Design Therapeutics has 74 Employees.
- Design Therapeutics grew their employee count by 23% last year.
Design Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Accounting Officer | Reveal Email/Phone |
2 | VP, Project Management | Reveal Email/Phone |
3 | VP Product Development | Reveal Email/Phone |
4 | VP Clinical Operations | Reveal Email/Phone |
5 | SVP Technology and Research | Reveal Email/Phone |
6 | VP, Early Development | Reveal Email/Phone |
7 | VP, Strategy and Operations | Reveal Email/Phone |
8 | Controller | Reveal Email/Phone |
9 | Associate Director Early Development | Reveal Email/Phone |
10 | Director, Drug Discovery Sciences, Chemistry at Design Therapeutics | Reveal Email/Phone |
Design Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is Design Therapeutics?
$170.7M
Total Funding
74
Number of Employees
$8.4M
Revenue (est)
23%
Employee Growth %
$882.3M
Valuation
N/A
Accelerator
Design Therapeutics News
The 57 rating InvestorsObserver gives to Design Therapeutics Inc (DSGN) stock puts it near the top of the Biotechnology industry.
Analysts expect Design Therapeutics, Inc. (NASDAQ:DSGN Get Rating) to post earnings of ($0.22) per share for the current fiscal quarter,...
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC gene...
Biotech company Design Therapeutics has set terms to raise as much as $240 million in its IPO. The company plans to sell 12 million shares for between $18 and $20 each in the offering. Design's top shareholders include SR One (10% post-IPO stake), Quan Funds (8.8%) and Cormorant (8.1%). View de ...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.5M | 74 | 28% | $824.7B |
#2 | $14.7M | 74 | 12% | N/A |
#3 | $6M | 74 | -6% | N/A |
#4 | $7.5M | 74 | 9% | N/A |
#5 | $15M | 74 | 7% | N/A |